LENZ Therapeutics (LENZ)

VIZZ is built around aceclidine, a miotic agent that constricts the pupil to improve depth of focus and help restore near vision. LENZ positions the product as differentiated because aceclidine acts primarily on the iris and is intended to produce pupil-selective effects with limited stimulation of the ciliary muscle. This distinction matters in the presbyopia category, where tolerability, duration of effect, and visual quality are important factors for patient adoption.

The company’s strategy centers on developing and commercializing ophthalmic pharmaceutical products that can be used conveniently and fit into daily routines. Its business depends on clinical execution, regulatory progress, physician and patient awareness, and market uptake in eye care channels. As a listed biotechnology company, LENZ combines the risk profile of drug development with the commercial opportunity of a potentially broad consumer-facing vision treatment market.